## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-37. (Cancelled)

- 38. (Previously presented) A compound chosen from 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy}quinazoline and its pharmaceutically acceptable salts.
- 39. (Currently amended) The compound according to claim 38, wherein said compound is 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl) piperidin-4-yl]-oxy}quinazoline.
- 40. (Currently amended) The compound according to claim 38, wherein said-compound is a A pharmaceutically acceptable salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy}quinazoline.
- 41. (Previously presented) A pharmaceutical composition comprising at least one compound chosen from 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy}quinazoline and its pharmaceutically acceptable salts in association with a pharmaceutically-acceptable diluent or carrier.
- 42. (Currently amended) The pharmaceutical composition according to claim 41, wherein said pharmaceutical composition comprises comprising 4-(3-chloro-2-

Application No. 10/571,991 Attorney Docket No. 09963.0008

fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl) piperidin-4-yl]oxy}-quinazoline in association with a pharmaceutically-acceptable diluent or carrier.

43. (Currently amended) The pharmaceutical composition according to claim 41, wherein said pharmaceutical composition comprises comprising a pharmaceutically acceptable salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]-oxy}quinazoline in association with a pharmaceutically-acceptable diluent or carrier.

Claims 44 - 71 (Cancelled)